UNSPSC 51362101: Bromamide

This classification denotes a sedative and hypnotic with the molecular formula C11H15BrN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GC4N5H35P2, chemically known as 3-(p-bromoanilino)-n,n-dimethylpropionamide but generally known as bromamid, which bears US NIH Compound Identifier 68839. European Medicines Agency schedules Bromamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05906MIG. The term BROMAMIDE is an International Non-Proprietary Name.

Most nations schedule bromamide under HS 29242995 and SITC 51479. SMILES: BRC1CCC(NCCC(=O)N(C)C)CC1.

UNSPSC 51362101 Bromamide is a Commodity code that nominally covers chemical compounds, but recent state and local solicitations under this code show minimal alignment with the code's stated scope. The available opportunities reflect a mismatch between the code classification and actual procurement activity: Seminole County, Florida issued an IFB for naloxone and drug deactivation systems (health-care supply procurement), the Texas Health and Human Services Commission posted an RFI on direct-to-manufacturer prescription programs (pharmacy benefit management), and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP for generic multi-source pharmaceuticals and OTC products (drug supply chain aggregation). None of these procurements involve bromamide specifically or chemical manufacturing as their primary scope. Issuing bodies include state health departments, county health agencies, and cooperative purchasing vehicles spanning multiple jurisdictions; MMCAP represents participating state and local government facilities across Minnesota, Oregon, and other alliance members.

Recent activity concentrates in Florida, Texas, and Minnesota. The Seminole County IFB (posted June 30, 2026; response deadline July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term with one-year renewal option. The MMCAP RFP (posted January 20, 2026; response deadline March 26, 2026) establishes multi-award pharmaceutical contracts effective July 1, 2026, with products distributed through three authorized wholesalers and weighted evaluation criteria favoring price competitiveness (75 percent) and cGMP/DSCSA compliance. The Texas HHS RFI (posted April 3, 2026; response deadline April 3, 2026) functions as a market-intelligence tool, seeking vendor capabilities for direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager arrangements. The code shows limited recent relevant activity; vendors pursuing work under this classification should verify that specific opportunities align with their product lines before responding.